A hybridoma cell line capable of stably secreting monoclonal antibodies against conotoxin μ-KIIIA-CTX
By developing hybridoma cell line 3E11 that can secrete anti-conotoxin μ-KIIIA-CTX monoclonal antibody, an ELISA-based detection method was established, and the problem of detecting conotoxin μ-KIIIA-CTX in the prior art was solved, and the problem of detecting conotoxin μ-KIIIA-CTX was achieved. High sensitivity and specificity detection have promoted its application in medical research and new drug research and development.
Patent Information
- Application Number
- CN202211280518.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-10-19
- Publication Date
- 2024-11-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing detection methods have failed to effectively detect conotoxin μ-KIIIA-CTX, and no corresponding monoclonal antibodies have been developed, limiting its application in medical research and new drug development.
A hybridoma cell line 3E11 that secretes anticonotoxin μ-KIIIA-CTX monoclonal antibody was developed, and an immunoassay based on monoclonal antibodies was established through enzyme-linked immunosorbent assay (ELISA) technology.
It realizes high sensitivity, specificity and accuracy detection of conotoxin μ-KIIIA-CTX, which is suitable for large-scale sample detection, laying the foundation for commercial development of high-quality enzyme-linked detection kits.
Smart Images

Figure CN115948346B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of antibody engineering and immune detection, and specifically relates to a hybridoma cell line 3E11 capable of secreting anti-conotoxin μ-KIIIA-CTX monoclonal antibody. Background Art
[0002] Conotoxin (CTX), secreted by the carnivorous mollusk Conus living in tropical oceans, is a small peptide toxin used to anesthetize prey. They are composed of 10 to 41 amino acid residues and are cysteine-rich animal neuropeptide toxins. They have the special function of specifically binding to various ion channels and receptors in animals. Conotoxins are of various types, novel structures, strong selectivity, and definite efficacy. They have excellent application prospects in addiction, anesthesia, analgesia, and research and treatment of mental illness, cancer, and heart disease, and have become a new source of neuroscience research and new drug development.
[0003] Conotoxin μ-KIIIA-CTX is a new superfamily conotoxin found in Asprella kinoshitai, belonging to the M-gene superfamily, μ family. Conotoxin μ-KIIIA-CTX contains 16 amino acids and can specifically act on sodium channel receptors. It contains six cysteine patterns, among which the disulfide bond connection modes in the natural state are mainly Cysl-Cys9, Cys2-Cys15 and Cys4-Cys16.
[0004] Conotoxin μ-KIIIA- CTX is the simplest member of its family. Its specific voltage-gated sodium channels (NaVs) have been shown to play an important role in pain in animals and humans, and its research has been quite popular in recent years. However, there are no reports on the detection method of conotoxin μ-KIIIA- CTX, nor on the development and application of monoclonal antibodies against conotoxin μ-KIIIA- CTX. Therefore, it is of great significance to prepare monoclonal antibodies against conotoxin μ-KIIIA- CTX and establish immunoassay methods based on monoclonal antibodies.
[0005] Enzyme-linked immunosorbent assay (ELISA) technology is developed on the basis of immunology. It combines immunologically active antigens or antibodies with enzymes to form enzyme-labeled antigens or enzyme-labeled antibodies with immunological and enzymatic activities, so that they can combine with the sample to be tested to form a complex product. Finally, the sample to be tested can be quantitatively analyzed through measurement. It has the characteristics of high sensitivity, strong specificity, simple operation and low cost. It has been widely used in modern medical research, food chemical analysis, biology and other major fields. Four technical methods have been developed: sandwich method, indirect method, direct method and competitive method.
[0006] Conotoxin μ-KIIIA-CTX is a small molecule polypeptide, which is more suitable for detection by ELISA method. At present, there is no ELISA immunoassay method based on monoclonal antibodies. Therefore, a hybridoma cell line that can stably secrete monoclonal antibodies against conotoxin μ-KIIIA-CTX is prepared to lay a solid foundation for the commercial development and production of high-quality enzyme-linked detection kits. Summary of the invention
[0007] The present invention aims to provide a hybridoma cell line 3E11 which can secrete anti-conotoxin μ-KIIIA-CTX monoclonal antibody.
[0008] To achieve the above object, the present invention adopts the following technical solution:
[0009] The present invention first provides a hybridoma cell line 3E11. The hybridoma cell line 3E11 is classified and named as anti-conotoxin μ-KIIIA-CTX monoclonal antibody hybridoma cell line. It was registered and preserved in the General Microbiology Center of China Microorganism Culture Collection on December 3, 2021. The preservation address is: No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing, and the preservation number is: CGMCC No. 45004.
[0010] The present invention also provides an anti-conotoxin μ-KIIIA-CTX monoclonal antibody, wherein the anti-conotoxin μ-KIIIA-CTX monoclonal antibody subtype is IgG1, V H and V L The variable region sequences are shown as SEQ ID NO.9 and SEQ ID NO.10, respectively, which are secreted by the hybridoma cell line 3E11 with a deposit number of CGMCC No. 45004; the preparation method of the anti-conotoxin μ-KIIIA-CTX monoclonal antibody is: the hybridoma cell line 3E11 is used to prepare ascites and purify to obtain the anti-conotoxin μ-KIIIA-CTX monoclonal antibody.
[0011] The present invention also provides the use of the above-mentioned anti-conotoxin μ-KIIIA-CTX monoclonal antibody in detecting the conotoxin μ-KIIIA-CTX.
[0012] The present invention also provides a conotoxin μ-KIIIA-CTX detection kit, which comprises the above-mentioned anti-conotoxin μ-KIIIA-CTX monoclonal antibody.
[0013] The significant advantages of the present invention are:
[0014] At present, there is no report on the development of monoclonal antibodies (IgG) for conotoxin μ-KIIIA-CTX, and there is no ELISA immunoassay method for conotoxin μ-KIIIA-CTX. Compared with the existing detection methods, the immunoassay method used in the present invention has the characteristics of good specificity, high sensitivity, high accuracy, simple operation, low cost, etc., and is suitable for large-scale sample detection. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 This is the SDS-page electrophoresis diagram of the expression and purification of the recombinant antigen of the present invention. Lane M: Protein Maker; Lane 1: Empty pET-32a total protein; Lane 2: pET-32a- μ-ctx Total protein; Lane 3-4: purified TRX-μCTX fusion protein; Lane 5: empty pGEX-6p-1 total protein; Lane 6: pGEX-6p-1- μ-ctx Total protein; Lanes 7-8: purified GST-μ-CTX fusion protein.
[0016] Figure 2 The present invention is to determine the serum titer of the immunized mice.
[0017] Figure 3 It is the cell fusion result of the present invention.
[0018] Figure 4 It is the result of antibody purification of the present invention. Lane M: Maker; Lane 1: ascites total protein; Lane 2: purified anti-conotoxin μ-KIIIA-CTX monoclonal antibody.
[0019] Figure 5 The present invention is a chromosome analysis of the hybridoma cell line.
[0020] Figure 6 It is the affinity test result of the monoclonal antibody of the present invention.
[0021] Figure 7 It is the specificity analysis result of the monoclonal antibody indirect ELISA of the present invention.
[0022] Figure 8 It is a standard detection curve diagram of the monoclonal antibody indirect competition ELISA of the present invention.
[0023] Fig. 9 It is a straight line diagram of the indirect competitive ELISA standard detection of the monoclonal antibody of the present invention. DETAILED DESCRIPTION
[0024] The following examples are used to illustrate the present invention but are not intended to limit the scope of the present invention.
[0025] The hybridoma cell line 3E11 of the present invention is classified and named as anti-conotoxin μ-KIIIA-CTX monoclonal antibody hybridoma cell line, and was registered and deposited in the General Microbiology Center of China Microorganism Culture Collection on December 3, 2021. The deposit address is: Institute of Microbiology, Chinese Academy of Sciences, No. 3, No. 1 Beiceng West Road, Chaoyang District, Beijing, and the deposit number is: CGMCC No. 45004.
[0026] Example 1 Preparation and identification of monoclonal antibodies
[0027] 1. Antigen carrier construction
[0028] (1) Obtaining the protein and gene sequences of the conotoxin μ-KIIIA-CTX (hereinafter referred to as μ-CTX)
[0029] The amino acid sequence of μ-CTX found in the literature (doi.org / 10.1074 / jbc.M704616200) is:
[0030] CCNCSSKWCRDHSRCC*
[0031] Based on the codon preference of E. coli BL21 (DE3), the DNA sequence of μ-CTX toxin was optimized (hereinafter referred to as μ-ctx gene), and then chemically synthesized. μ-ctx The nucleotide sequence of the gene is as follows:
[0032] 5'-TGCTGCAACTGCTCTAGCAAATGGGTGCCGTGATCACAGCCGTAGCTGC-3'
[0033] 2) μ-ctx Gene synthesis
[0034] μ-ctx The gene is only 48bp, so a single-stranded gene fragment (primer) containing the entire gene sequence and a portion of deoxynucleotides with an enzyme cleavage site was chemically synthesized. The primer sequence is as follows:
[0035] μ-ctx -F- XOt I:
[0036] 5'- TCGAG TGCTGCAACTGCTCTAGCAAATGGTGCCGTGATCACAGCCGTAGCTGC -3'
[0037] μ-ctx -R- EcoR Ⅰ:
[0038] 5'- AATTC GCAGCTACGGCTGTGATCACGGCACCATTTGCTAGAGCAGTTGCAGCA-3'
[0039] After the two primers anneal and complement each other, the inserted fragment is formed and can be directly combined with the same XOt I. EcoR Ⅰ Double restriction enzyme digested plasmid was connected.
[0040] 3) Recombinant plasmid pET-32a- μ-ctx Construction
[0041] use XOt I and EcoR Ⅰ Double enzyme digestion of pET-32a vector to obtain XOt I and EcoR The linear plasmid, insert fragment and T4-DNA ligase were mixed and connected overnight to obtain the recombinant plasmid pET-32a- μ-ctx , the above recombinant plasmid was transformed into E. coli BL21(DE3) competent cells were plated on LB+ Ampicillin (final concentration 100 μg / mL) plates.
[0042] 3) Recombinant plasmid pGEX-6p-1- μ-ctx Construction
[0043] use XOt I and EcoR Ⅰ Double restriction digestion of pGEX-6p-1 vector to obtain XOt I and EcoR The linear plasmid pGEX-6p-1 with sticky ends of the restriction site was mixed with the above linear plasmid, the inserted fragment, and T4-DNA ligase, and ligated overnight to obtain the recombinant plasmid pGEX-6p-1- μ-ctx, The above recombinant plasmid was transformed into E. coli BL21(DE3) competent cells were plated on LB+ Ampicillin (final concentration 100 μg / mL) plates.
[0044] 4) Screening and detection of recombinant plasmids
[0045] Several single colonies on the above plates were picked up and inoculated into 700 μL LB liquid culture medium. After culturing at 180 r / min on a shaker for 45 min, the bacteria were sent for sequencing and identification. The strains with correct sequencing were named pET-32a- μ-ctx / BL21(DE3) and pGEX-6p-1- μ-ctx / BL21(DE3). Take 40 μL of the correctly sequenced bacterial solution and inoculate it into 4 mL LB+Ampicillin (final concentration 100 μg / mL) liquid medium, and culture it at 37°C and 180 r / min shaking for 8 h. The bacterial solution was used as seed solution for subsequent experiments.
[0046] 2 Expression and purification of recombinant antigens
[0047] 1) strain pET-32a- μ-ctx / BL21(DE3) activation and TRX-μ-CTX fusion protein expression and purification
[0048] Take 1 mL of fresh bacterial solution and inoculate it into 100 mL of LB liquid medium (100 μg / mL Ampicillin), and culture it in a shaking incubator at 37°C and 180 r / min for 2-3 h. When the OD600 nm of the bacterial solution is 0.6-0.8, add 100 μL of 1 mol / L isopropylthiogalactoside (IPTG) and culture it in a shaking incubator at 25°C overnight.
[0049] Collect 33 mL of bacterial solution into a clean centrifuge tube, centrifuge in a 4℃ refrigerated centrifuge for 10 min at 8000 r / min. After centrifugation, discard the supernatant, collect the bacterial precipitate in the centrifuge tube, and then add 7 mL of pre-prepared Buffer A (70 mM NaH2PO4·2H2O+0.3 M NaCl+10 mM C3H4N2, pH8.0) solution to the precipitate to resuspend the bacteria. Use an ultrasonic disruptor to disrupt, work for 5 s, pause for 10 s, until the bacterial solution turns from turbid to clear. Place the ultrasonically disrupted bacterial solution in a 4℃ refrigerated centrifuge for 10 min at 10000 r / min, and collect the supernatant after centrifugation. Loading: Add the supernatant to the Ni pre-equilibrated with Buffer A solution. 2+ -NTA affinity chromatography column, repeatedly apply to the column for about 1 hour (10 cycles). Wash: After applying to the column, flow through 250 mL Buffer B (70 mM NaH2PO4·2H2O+0.3 M NaCl+50 mM C3H4N2, pH8.0) to remove impurity protein molecules. Elution: Finally, use Buffer C (70 mM NaH2PO4·2H2O+0.3 M NaCl+250 mM C3H4N2, pH8.0) to elute and collect the target protein.
[0050] 2) Strain pGEX-6p-1- μ-ctx / BL21(DE3) activation and GST-μ-CTX fusion protein expression and purification
[0051] Take 1 mL of fresh bacterial solution and inoculate it into 100 mL LB liquid medium (100 μg / mL Ampicillin), and culture it in a shaking incubator at 37°C and 180 r / min for 2-3 h. When the OD600 nm of the bacterial solution is 0.6-0.8, add 100 μL of 1 mol / L isopropylthiogalactoside (IPTG) to the solution, and the final concentration of the system is 1 mmol / L. Culture it in a shaking incubator at 20°C overnight.
[0052] Collect 33 mL of bacterial solution into a clean centrifuge tube, place it in a 4℃ refrigerated centrifuge and centrifuge for 10 min at 8000 r / min. After centrifugation, discard the supernatant, collect the bacterial precipitate in the centrifuge tube, and then add 7 mL of 0.01M pH7.4 PBS buffer to the precipitate to resuspend the bacteria. Use an ultrasonic disruptor to disrupt, work for 5 s, pause for 10 s, until the bacterial solution changes from turbid to clear. Place the ultrasonic disrupted bacterial solution in a 4℃ refrigerated centrifuge and centrifuge for 10 min at 10000 r / min. Collect the supernatant after centrifugation. Column: Add the supernatant to the GST affinity chromatography column equilibrated with 0.01M pH7.4 PBS buffer in advance, repeatedly bind to the column for about 2 h, and cycle 8 times. Wash: After the column is completed, pass 200 mL of 0.01M pH7.4 PBS buffer to wash away the impurity protein molecules. Elution: Finally, the target protein was eluted and collected with GSH solution (10 mmol / mL GSH + 50 mmol / mL Tris-HCl, pH 8.0).
[0053] 3) Protein verification
[0054] Take 20 μL of the purified protein solution, add 10 μL of 5×SDS-PAGE loading buffer, mix thoroughly with a pipette, boil in water for 10 min, centrifuge and take 10 μL of the supernatant for SDS-PAGE electrophoresis analysis. The results are as follows: Figure 1 shown.
[0055] 3 Preparation of monoclonal antibodies
[0056] 1) Mouse immunization
[0057] 6-8 week old females were immunized with the complete antigen GST-μ-CTX prepared above. Balb / c Mouse.
[0058] For the first immunization, an equal volume of Freund's complete adjuvant was mixed with the complete antigen GST-μ-CTX, and the mixture was emulsified to an oil-in-water state using an emulsifier. The emulsification result was judged by whether it would not disperse immediately when dropped into water. After emulsification, Balb / c mice were injected subcutaneously at multiple points. The antigen injection dose was 100 μg / mouse and the injection volume was 200 μL / mouse. Subsequent immunizations were performed every 14 days. After the first immunization, Freund's complete adjuvant was replaced with Freund's incomplete adjuvant, and the antigen injection dose was adjusted to 50 μg / mouse. The other steps were the same as the first immunization. After three immunizations, blood was collected from the tail, and the enzyme label strip was coated with TRX-μ-CTX fusion protein as the inspection antigen, and the serum titer was detected by iELISA. Until the mouse antiserum titer was OD at a dilution of 1:8000. 450 When the value exceeds 1, the cell fusion condition is achieved, such as Figure 2 The figure shows the antiserum titer test one week after the third immunization. If the titer is not reached, the mice can continue to be immunized according to the conventional method until the titer reaches the standard. If the titer of the mice selected on the same day reaches the standard and has μ-CTX specificity, the complete antigen GST-μ-CTX is diluted with normal saline at 30μg / 100μL / mouse, filtered and sterilized, and then directly injected into the mouse peritoneal cavity for the final booster immunization to prepare for cell fusion.
[0059] 2) Immune serum titer determination
[0060] Within 5-7 days after the third immunization of mice, the titer of mouse antiserum was detected by indirect enzyme-linked immunosorbent assay (iELISA). The operation steps are as follows:
[0061] (1) Antiserum collection: Blood was collected from the tail vein of mice. The blood was placed in a 37°C water bath for 30 min, then centrifuged at 12,000 rpm for 20 min at 4°C. The upper serum was aspirated and set aside.
[0062] (2) Coating: Dilute the detection antigen TRX-μ-CTX fusion protein prepared above to a final concentration of 5 μg / mL with coating buffer CBS (1.59 g Na2CO3 and 2.93 g NaHCO3 dissolved in distilled water and fixed to 1 L, pH = 9.6), add to the enzyme label strip, 100 μL per well, place in a 4°C refrigerator for incubation overnight, and then pour out the antigen.
[0063] (3) Blocking: Prepare PBSM solution (5 wt% skim milk powder + 0.01 M PBS buffer, pH 7.4), add 200 μL / well to the ELISA wells, place in a 4°C refrigerator for one day, wash the plate three times with 0.01 M PBS buffer, pH 7.4, and pat dry after washing.
[0064] (4) Primary antibody: Use PBSM solution to dilute the antiserum collected in step (1) with a starting dilution of 1:500, add 100 μL to each well of the enzyme-labeled plate, and incubate in a 37°C incubator for 1 h. Use PBSM solution as a negative control. Pour out the liquid in the wells, wash the plate 3 times with PBS (0.01M pH7.4) and PBST (Vtween20 / VPBS = 0.05%), and pat dry after washing.
[0065] (5) Secondary antibody: Dilute the enzyme-labeled secondary antibody (sheep anti-mouse-coupled horseradish peroxidase, HAMA-HRP) with PBSM solution at a dilution ratio of 1:8000, add 100 μL of secondary antibody to each well, and incubate in a 37°C incubator for 45 min. Then pour out the liquid in the wells, wash the plate three times with PBS (0.01M pH7.4) and PBST, and pat dry after washing.
[0066] (6) Color development: Take TMB A solution (17 mM C6H8O7 + 0.33 M CH3COONa + 0.3 mL 30% H2O2) and TMBB solution (10 mM C6H8O7 + 1.2 mM C 10 H 14 N2Na2O8+1.8 mM TMB+50 mL Glycerol), mix the two in equal volumes to obtain TMB colorimetric solution, use a pipette to draw TMB colorimetric solution at 100 μL / well and add it to the enzyme-labeled wells, and incubate in a 37°C incubator for 15 min.
[0067] (7) Termination: Take out the ELISA plate after color development and immediately add 2M H2SO4 solution to the wells to terminate the color development reaction, 50 μL per well. After color development is terminated, place the ELISA plate in an ELISA reader to detect the OD450 nm value.
[0068] 3) Cell fusion
[0069] One week after the fifth immunization, booster immunization was performed. On the third day, the spleen of the mouse was taken and spleen cells were obtained by grinding and filtration. SP2 / 0 cells: spleen cells = 3:1 were mixed, centrifuged at room temperature for 7 min at 1100 r / min, the supernatant was discarded, and the centrifuge tube was flicked until the cell pellet was loose. The centrifuge tube containing the cell pellet was placed in a 37°C warm water bath, and 1 mL of preheated 50% (w / v) PEG 1450 solution was slowly added to it. The dropping process was based on the principle of slow first and fast later, and it was added within 1 min, and then it was allowed to stand for 1 min. After standing, 40 mL of preheated 1640 incomplete culture medium was slowly added to terminate the fusion. According to the principle of slow first and fast later, 1 mL of culture medium was slowly added in the first minute, 3 mL of culture medium was added in the second minute, and 5 mL of culture medium was added in the third minute, and so on, until 40 mL of 1640 incomplete culture medium was added, and then the cell mixture was placed in a CO2 incubator and allowed to stand for 10 min. After standing, centrifuge the cell mixture at room temperature for 7 min at 1100 r / min, discard the supernatant, transfer the cell pellet to a sterile glass bottle containing 100 mL preheated 2 vol% HAT complete medium (containing 20 vol% fetal bovine serum), shake the glass bottle gently to disperse the cells, and then put it in a CO2 incubator to stand for 10 min. Then use an 8-hole gun to add the fused cells to the 96-well plate pre-plated with feeder cells, 100 μL per well, and plate 10 plates. After cell fusion, observe the cell growth, such as Figure 3 shown.
[0070] 4) Screening of positive hybridoma cells
[0071] On the 8th day after cell fusion, the fused cells were screened by iELISA. The TRX-μ-CTX fusion protein was diluted to a concentration of 5μg / mL, 100μL / well, with coating buffer CBS (1.59g Na2CO3 and 2.93g NaHCO3 dissolved in distilled water and fixed to 1L, pH9.6), and sealed, and 10 plates were coated. The culture supernatant in the cell culture plate was taken with an 8-well gun, 100 μL was taken from each well, added to the ELISA plate, and placed in a 37°C incubator for incubation for 1 h. At the same time, each well of the cell culture plate was supplemented with 120μL 2vol% HAT complete medium. After 1 hour, wash three times with 0.01M PBST, and then wash three times with 0.01M PBS. After patting dry, add diluted goat anti-mouse-HRP, 100μL per well, and incubate in a 37℃ incubator for 1 hour. Then add the prepared TMB colorimetric solution, 100μL per well, and place in a 37℃ incubator for 15 min. Take out the ELISA plate, add 50μL 2M H2SO4 solution to terminate the color development reaction, and then measure the OD450 nm value. At the same time, use the serum of the fused mouse as a positive control. Take the positive control value as a reference, and pick a single cell colony from the positive well of the fused cell and transfer it to a new well for culture. After a period of time, use the icELISA method for titer detection (retest) and specificity detection, select hybridoma cells in good condition, subclone by limiting dilution method, and detect the subtype of cell-secreted antibodies. Finally, obtain the hybridoma cell line 3E11 that can stably secrete monoclonal antibodies.
[0072] 5) Preparation and purification of ascites
[0073] Hybridoma cell line 3E11 was cultured at 1×10 6 cells / mouse were injected into the abdominal cavity of female Balb / c mice that had been paraffin-sensitized for one week. The mice were observed after one week. When the abdomen of the mice was swollen and tense, the ascites was extracted and then centrifuged at 4°C for 20 minutes at a speed of 13000r / min. After centrifugation, it can be observed that the ascites is divided into three layers (from bottom to top, cell precipitation, clear and transparent layer containing a large amount of monoclonal antibodies, and lipid layer). The middle liquid layer was aspirated with a pipette and placed in a new EP tube, which was then sealed with a sealing film and stored in a -80°C ultra-low temperature refrigerator. The antibodies secreted by the hybridoma cell line 3E11 belong to the IgG1 type antibody. The monoclonal antibody was purified from the ascites by Protein G affinity chromatography, and the antibody protein concentration was determined by the BCA method. Then, the purity of the antibody was verified by 10% SDS-PAGE gel electrophoresis. Figure 4As shown in the figure, the purified antibody has obvious bands at 40-50 kDa and 25-30 kDa, corresponding to the heavy chain and light chain of IgG1 antibody, respectively, and there are almost no mixed bands, indicating that the Protein G affinity chromatography medium method is very effective in purifying IgG1 antibody. The purified monoclonal antibody (mAb 3E11) was then stored at -80°C.
[0074] 4 Characterization of monoclonal antibodies
[0075] 1) Chromosome analysis: Hybridoma cells 3E11 in the logarithmic growth phase were treated with 0.1wt% colchicine (0.5 μg / L). After culturing for 6 h, the cell cycle was synchronized to the metaphase of mitosis. The cells were suspended and the cell resuspension was collected into a 15 mL centrifuge tube. The tube was centrifuged at room temperature for 8 min at a speed of 1200 r / min. After centrifugation, the supernatant was gently poured off and 10 mL of 0.075 mol / L potassium chloride solution was added to the cell pellet in each tube. The cells were gently blown up with a pipette and the cell suspension was placed in a 37°C incubator for another 30 min. Add 1 mL of freshly prepared methanol-acetic acid fixative (methanol: acetic acid volume ratio is 3:1) to the cell suspension, shake well, let stand at room temperature for 5 min, centrifuge at room temperature at 1200 r / min for 8 min, add 5 mL of freshly prepared methanol-acetic acid fixative to the centrifuged precipitate again, gently blow up the cell precipitate with a pipette, let stand at room temperature for 30 min, then centrifuge at room temperature at 1200 r / min for 8 min, add 5 mL of freshly prepared methanol-acetic acid fixative to the centrifuged precipitate, blow up and shake well with a pipette, and place in a 4°C refrigerator overnight. Take out the next day and centrifuge at room temperature at 1200 r / min for 8 min, blow up and shake the centrifuged cell precipitate with 300 μL of freshly prepared methanol-acetic acid fixative. Add 10 μL of cell suspension to the frozen slide, blow it away immediately, dry it naturally, stain it with a newly prepared 1:10 Giemsa phosphate buffer for 10-15 min, rinse with distilled water, dry it, and then examine it under a microscope, microphotograph it, and analyze the karyotype. like Figure 5 As shown, the positive hybridoma cells 3E11 were treated with 0.1wt% colchicine, stained and observed under a microscope, and the chromosome number of the hybridoma cells in metaphase was calculated to be 103±5. The chromosome number of the hybridoma cells was close to the sum of the chromosome numbers of the two parents, proving that the positive hybridoma cells were formed by the fusion of myeloma cells and spleen cells.
[0076] 2) Monoclonal antibody affinity determination
[0077] According to the Beatty method (doi.org / 10.1016 / 0022-1759(87)90187-6), the affinity constant Kaff of monoclonal antibodies was determined by iELISA. TRX-μ-CTX fusion protein was diluted to 10μg / mL, 5μg / mL, 2.5μg / mL, 1.25μg / mL, and 0.625μg / mL in coating buffer CBS and coated in ELISA enzyme-labeled plates. The purified monoclonal antibodies were diluted in 5% PBSM as primary antibodies, and the antibodies were diluted to 59.6ng / mL, 29.8ng / mL, 14.9ng / mL, 7.45ng / mL, 3.73ng / mL, 1.863ng / mL, 0.933ng / mL, and 0.466ng / mL, respectively. Take out the pre-coated ELISA plate, add antibodies of different dilutions to each ELISA strip from top to bottom to form an orthogonal chessboard, add 100 μL to each well, and the rest of the steps are the same as the above iELISA test.
[0078] Record data and analyze and calculate the concentration gradient of TRX-μ-CTX fusion protein antigen in IC 50 The affinity constant of the monoclonal antibody can be calculated according to the following formula:
[0079]
[0080] In the above formula: the value of [Ab] is the antibody concentration at IC50 when the antigen concentration is [Ag];
[0081] The value of [Ab]t is the antibody concentration at IC50 when the antigen concentration is [Ag]t;
[0082] n is the ratio of [Ag] to [Ag]t
[0083] The results of the test are as follows Figure 6 As shown, Origin8.0 software was used to make the fitting curves. 50 According to the affinity constant determination formula, the affinity of the antibody was calculated to be 5.838×10 8 L / mol.
[0084] 1) Monoclonal antibody specificity iELISA specificity analysis
[0085] The specificity of monoclonal antibodies was determined by iElISA detection method. Different complete antigens (TRX-μ-CTX fusion protein, GST-μ-CTX fusion protein, TRX-αB-CTX fusion protein, GST-αB -CTX fusion protein, TRX-ω-CTX fusion protein, sea snake toxin SN311, short-chain neurotoxin SN285) were diluted with coating buffer CBS to a concentration of 10μg / mL, and coated into 96-well ELISA plates at 100 μL per well using a pipette. The antibody was diluted to a concentration of 14.9ng / mL with 5% PBSM solution, and then added to the coated ELISA plates at 100 μL per well. A negative control group was also made at the same time. The specific operation steps of the experiment were the same as those of the iELISA method. Finally, the OD450 nm value was determined and the data was recorded. The results showed that the antibody had good specificity, as shown in Figure 2. Figure 7 Among them, TRX-αB-CTX fusion protein, GST-αB-CTX fusion protein, and TRX-ω-CTX fusion protein were provided by the Key Laboratory of Pathogenic Fungi and Mycotoxins of Fujian Province, and the sea snake toxin SN311 and short-chain neurotoxin SN285 were provided by Sangon Biotech (Shanghai) Co., Ltd.
[0086] 2) Determination of amino acid sequence of variable region of monoclonal antibody
[0087] ① Extraction of total RNA from hybridoma cells and acquisition of cDNA
[0088] A commercial RNA extraction kit was used to extract total RNA from hybridoma cells. The kit was MolPure ® Cell / Tissue Total RNA Kit (Cat. No. 19221ES08).
[0089] cDNA was obtained using a commercial RNA reverse transcription kit to obtain cDNA from hybridoma cells. The kit is Hiscript ® II 1 st Strand cDNA Synthesis Kit (Cat. No. R211-01 / 02).
[0090] ②V H 、V L Gene PCR amplification
[0091] (a) For amplification of V H 、V L The primer sequences of the genes are as follows:
[0092]
[0093] Note: M=A / C, R=A / G, S=C / G, W=A / T
[0094] (b) Using cDNA as template, V H -R / V H -F and V L -R / V L -F primers to V H and V L Amplification was performed, and the amplification procedure was as follows:
[0095]
[0096] The PCR reaction system is as follows:
[0097]
[0098] After completion, the PCR product was recovered using a DNA recovery kit, the kit being GeneJET Gel Extraction kit (product number: #K0692).
[0099] (c) Using a commercial TA cloning kit, V H and V L The PCR products were cloned into T vectors, and the kit was pMD TM 18-T Vector Cloning Kit (Product No.: 6011), the above recombinant plasmid was transformed into E. coli DH5α competent cells were spread on LB+ Ampicillin (final concentration 100 μg / mL) plates. Multiple single colonies on the above plates were picked and inoculated into 700 μL LB+ Ampicillin (final concentration 100 μg / mL) liquid culture medium. After culturing on a shaking table at 180 r / min for 45 minutes, the bacteria were sent for sequencing and identification to obtain V H and V L The amino acid sequences are shown in SEQ ID NO.9 and SEQ ID NO.10 respectively.
[0100] 5) Monoclonal antibody competition curve and standard curve
[0101] First, the optimal working concentrations of antigen coating and primary antibody dilution should be determined. The TRX-μ-CTX fusion protein antigen was diluted to 10μg / mL, 5μg / mL, 2.5μg / mL, 1.25μg / mL, and 0.625μg / mL with coating buffer CBS. The purified antibody solution was diluted with 5% PBSM, and finally the antibody was diluted to 59.6ng / mL, 29.8ng / mL, 14.9ng / mL, 7.45ng / mL, 3.73ng / mL, 1.863ng / mL, 0.933ng / mL, and 0.466ng / mL. The iELISA experiment was performed using the chessboard method, and the point with OD450nm close to 1 was selected. The corresponding antigen coating concentration and primary antibody dilution concentration were the optimal working concentrations. The optimal concentration of antigen coating was 5 μg / mL, and the optimal concentration of primary antibody dilution was 14.9 ng / mL.
[0102] The determined coating antigen concentration and primary antibody working concentration were used for icELISA to establish a standard competition curve for CTX. Coated with TRX-μ-CTX fusion protein antigen (5 μg / mL), μ-KIIIA-CTX standard (hereinafter referred to as μ-CTX standard) (provided by Shanghai Biotech Co., Ltd.) was diluted with 5% PBSM solution to concentrations of 10000 ng / mL, 5000 ng / mL, 2500 ng / mL, 1250 ng / mL, 625 ng / mL, 312.5 ng / mL, 156.25 ng / mL, 9.7656 ng / mL, 2.4414 ng / mL, 0.305175 ng / mL, 0.152588 ng / mL, 0.076294 ng / mL, 0.038147 ng / mL, 0.019073 ng / mL, 0.009537 ng / mL, 0.004768 ng / mL , 0.002384 ng / mL, 0.001192ng / mL, mix the diluted μ-CTX standard solution with the anti-μ-CTX monoclonal antibody diluted to 14.9 ng / mL in equal volumes (the final antibody concentration is halved compared to the antibody concentration before mixing), incubate in a 37°C constant temperature incubator for 1 hour, then take 100μL of the mixed solution from each tube and add it to the enzyme-labeled well (the concentration of the antigen coating is 5 μg / mL, and the coating steps are the same as above), and do positive and negative controls at the same time. The positive control is the antibody solution mixed with equal volumes of PBSM for incubation, then 100 μL is taken out and added to the enzyme-labeled well, and the negative control is 100 μL of PBSM is added to the enzyme-labeled well, and then the iELISA method is used. The obtained data were processed, with the horizontal axis being the logarithmic value of μ-CTX standard concentration and the vertical axis being B / B0, where B is the OD450 nm value measured in the test well and B0 is the OD450 nm value measured in the positive well. The competition curve and the standard curve were fitted using Origin 8.0. Figure 8 , the curve equation is y=0.06043+[(1.0175-0.06043) / (1+x / 3.45591) 0.7791 ], R 2 =0.99528, where IC50=4.21ng / mL, the lowest detectable concentration of μ-CTX is calculated to be about 0.72 ng / mL. 20 ~IC 80 There is a good linear relationship between them, so the points in this linear interval are refitted into a standard straight line, such as Fig. 9 , formula y=0.72661-0.34713x, and the linear detection range of μ-CTX was calculated to be 0.72~33.02 ng / mL.
[0103] The above description is only a preferred embodiment of the present invention. All equivalent changes and modifications made according to the scope of the patent application of the present invention should fall within the scope of the present invention.
Claims
1. A hybridoma cell line 3E11 producing monoclonal antibodies against conotoxin μ-KIIIA-CTX, characterized in that: The hybridoma cell line 3E11 was registered and deposited at the General Microbiology Center of China Culture Collection Administration on December 3, 2021. The deposit address is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is: CGMCC No.45004.
2. An anti-conotoxin μ-KIIIA-CTX monoclonal antibody, characterized in that: The anti-conotoxin μ-KIIIA-CTX monoclonal antibody subtype is IgG1, which is secreted and produced by the anti-conotoxin μ-KIIIA-CTX monoclonal antibody hybridoma cell line 3E11 with a deposit number of CGMCC No.45004; the V H Variable region sequences and V L The variable region sequences are shown in SEQ ID NO.9 and SEQ ID NO.10 respectively.
3. A method for preparing the anti-conotoxin μ-KIIIA-CTX monoclonal antibody according to claim 2, characterized in that: The hybridoma cell line 3E11 is used to prepare ascites and purify the ascites to obtain the anti-conotoxin μ-KIIIA-CTX monoclonal antibody.
4. Use of the anti-conotoxin μ-KIIIA-CTX monoclonal antibody according to claim 2 in the preparation of a kit for detecting conotoxin μ-KIIIA-CTX.
5. A conotoxin μ-KIIIA-CTX detection kit, characterized in that: The conotoxin μ-KIIIA-CTX detection kit comprises the anti-conotoxin μ-KIIIA-CTX monoclonal antibody according to claim 2.
